Role of cancer-related inflammation in esophageal cancer

Critical Reviews in Eukaryotic Gene Expression

Volumn 23, Issue 1, 2013, Pages 27-35

  Zhang, Mingxin ^a   Zhou, Suna ^a   Zhang, Lingmin ^b   Ye, Wenguang ^a   Wen, Qinsheng ^a   Wang, Jingjie ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cancer related inflammation; Esophageal cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MICRORNA 21; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; BARRETT ESOPHAGUS; CANCER RELATED INFLAMMATION; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HUMAN; INFLAMMATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CHEMOKINES; CYCLOOXYGENASE 2; CYTOKINES; ESOPHAGEAL NEOPLASMS; HUMANS; INFLAMMATION; MICRORNAS; PROGNOSIS; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS;

EID: 84875539086     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.2013006033     Document Type: Review

References (75)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related infammation. Nature. 2008;454:436-44.
2. Balkwill F, Mantovani A. Infammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
3. Kamangar F, Abnet CC, Hutchinson AA, Newschaf-fer CJ, Helzlsouer K, Shugart YY, Pietinen P, Dawsey SM, Albanes D, Virtamo J, Taylor PR. Polymorphisms in infammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control. 2006;17:117-125.
4. Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC. Association of infammation-related and microRNA gene expression with cancer-specifc mortality of colon ad-enocarcinoma. Clin Cancer Res. 2009;15:5878-5887.
5. Witz IP. Tumor-microenvironment interactions: Dangerous liaisons. Adv Cancer Res. 2008;100:203-229.
6. Krasna MJ. Multimodality therapy for esophageal cancer. Oncology (Williston Park). 2010;24:1134-1138.
7. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology. 2010;138:854-869.
8. Solaymani-Dodaran M, Logan RF, West J, Card T, Coup-land C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal refux. Gut. 2004;53:1070-1074.
9. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related infammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073-1081.
10. Hussain SP, Harris CC. Infammation and cancer: An ancient link with novel potentials. Int J Cancer. 2007;121:2373-2380.
11. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related infammation. Ann Med. 2010;42:161-170.
12. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinker-nagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature. 2008;453:807-811.
13. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour mi-croenvironment. Nat Rev Immunol. 2007;7:41-51.
14. Lazennec G, Richmond A. Chemokines and chemokine receptors: New insights into cancer-related infammation. Trends Mol Med. 2010;16:133-144.
15. Allavena P, Germano G, Marchesi F, Mantovani A. Che-mokines in cancer related infammation. Exp Cell Res. 2011;317:664-673.
16. Schmid RM, Adler G. NF-κB/rel/IκB: implications in gastrointestinal diseases. Gastroenterology. 2000;118:120828.
17. Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, Cole G Jr, Schrump DS. Potentiation of paclitaxel cy-totoxicity in lung and esophageal cancer cells by phar-macologic inhibition of the phosphoinositide 3-kinase/ protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg. 2004;127:365-375.
18. Abdel-Latif MM, Raouf AA, Sabra K, Kelleher D, Reynolds JV. Vitamin C enhances chemosensitiza-tion of esophageal cancer cells in vitro. J Chemother. 2005;17:539-549.
19. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006;5:2844-2850.
20. Lee JS, Oh TY, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Kim HJ, Hahm KB. Involvement of oxidative stress in experimentally induced refux esophagitis and Barrett's esophagus: clue for the chemoprevention of esoph-ageal carcinoma by antioxidants. Mutat Res. 2001;480-481:189-200.
21. Abdel-Latif MM, Kelleher D, Reynolds JV. Potential role of NF-κB in esophageal adenocarcinoma: As an emerging molecular target. J Surg Res. 2009;153:172-180.
22. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadaflopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487-496.
23. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal ad-enocarcinoma cells. Cancer Res. 2000;60:5767-5772.
24. Yang GZ, Li L, Ding HY, Zhou JS. Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-κB: An immunohis-tochemical study. Exp Mol Pathol. 2005;79:214-218.
25. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748-754.
26. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-κB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491-500.
27. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
28. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635.
29. Sasse J, Hemmann U, Schwartz C, Schniertshauer U, Heesel B, Landgraf C, Schneider-Mergener J, Heinrich PC, Horn F. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol. 1997;17:4677-4686.
30. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour mi-croenvironment. Nat Rev Immunol. 2007;7:41-51.
31. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105.
32. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med. 2004;10:48-54.
33. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314-1321.
34. Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, Wang DH, Spechler SJ, Souza RF. Cancer-related in-fammation and Barrett's carcinogenesis: Interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol. 2011;300:G454-G460.
35. Liu JR, Wang Y, Zuo LF, Li FL, Wang Y, Liu JL. Expression and clinical signifcance of COX-2, p-Stat3, and p-Stat5 in esophageal carcinoma. Ai Zheng. 2007;26:458-462.
36. Du XL, Yang H, Liu SG, Luo ML, Hao JJ, Zhang Y, Lin DC, Xu X, Cai Y, Zhan QM, Wang MR. Calreticulin promotes cell motility and enhances resistance to anoi-kis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene. 2009;28:3714-3722.
37. Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, Wang Y, Lu N, Zhu H, Xu N. β-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008;271:85-97.
38. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-in-ducible factor 1 is a basic-helix-loop-helix-PAS heterodi-mer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510-5514.
39. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol. 2008;141:325-334.
40. Hieber S, Huhn R, Hollmann MW, Weber NC, Preckel B. Hypoxia-inducible factor 1 and related gene products in anaesthetic-induced preconditioning. Eur J Anaesthesiol. 2009;26:201-206.
41. Takala H, Saarnio J, Wiik H, Ohtonen P, Soini Y. HIF-1α and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res. 2011;167:41-48.
42. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, Tanimoto T, Uenoyama M, Ozeki Y, Maehara T. Expression of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma. Cancer Sci. 2005;96:176-182.
43. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL. Hypox-ia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001;61:1830-1832.
44. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic infammation. J Physiol. 2008;586:4055-4059.
45. Dvorak K, Chavarria M, Payne CM, Ramsey L, Crow-ley-Weber C, Dvorakova B, Dvorak B, Bernstein H, Holubec H, Sampliner RE, Bernstein C, Prasad A, Green SB, Garewal H. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res. 2007;13:5305-5313.
46. Rollins BJ. Infammatory chemokines in cancer growth and progression. Eur J Cancer. 2006;42:760-767.
47. Lazennec G, Richmond A. Chemokines and chemokine receptors: New insights into cancer-related infamma-tion. Trends Mol Med. 2010;16:133-144.
48. Allavena P, Germano G, Marchesi F, Mantovani A. Che-mokines in cancer related infammation. Exp Cell Res. 2011;317:664-673.
49. Wang DF, Lou N, Zeng CG, Zhang X, Chen FJ. Expression of CXCL12/CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma. Ai Zheng. 2009;28:154-158.
50. Kaif JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005;97:1840-1847.
51. Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, Drescher D, von Langsdorff C, Domeyer M, Biester-feld S, Galle PR, Junginger T, Moehler M. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer. 2006;6:290.
52. Lu CL, Ji Y, Ge D, Guo J, Ding JY. The expression of CXCR4 and its relationship with matrix metalloprotein-ase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Dis Esophagus. 2011;24:283-290.
53. Maruyama T, Kono K, Izawa S, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to infltration of regulatory T cells in esophageal squa-mous cell carcinoma. Dis Esophagus. 2010;23:422-429.
54. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV. Proinfammatory cytokine and nuclear factor κ-B expression along the infammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257-1264.
55. Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, Farthing MJ. Infammatory gradient in Barrett's oesophagus: Implications for disease complications. Gut. 2002;51:316-322.
56. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffths AP, Baxter JN, Parry JM. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-κB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis. 2004;25:317-323.
57. Dvorakova K, Payne CM, Ramsey L, Holubec H, Sam-pliner R, Dominguez J, Dvorak B, Bernstein H, Bernstein C, Prasad A, Fass R, Cui H, Garewal H. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res. 2004;10:2020-2028.
58. von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M. Overexpression of TGF-β1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Car-cinog. 2006;45:786-794.
59. Gholamin M, Moaven O, Memar B, Farshchian M, Nas-eh H, Malekzadeh R, Sotoudeh M, Rajabi-Mashhadi MT, Forghani MN, Farrokhi F, Abbaszadegan MR. Overex-pression and interactions of interleukin-10, transforming growth factor β, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 2009;33:1439-1445.
60. Xin Z, Wenyu F, Shenhua X. Clinicopathologic signif-cance of cytokine levels in esophageal squamous cell carcinoma. Hepatogastroenterology. 2010;57:1416-1422.
61. Chen PC, Feng JG, Ling YT. Expression of cytokines Th1 and Th2 in patients with esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2007;29:850-851.
62. Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Otsuji E. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 2011;31:67-75.
63. Okamura S, Fujiwara H, Suchi K, Okamura H, Umehara S, Todo M, Kuriu Y, Ikoma H, Kubota T, Nakanishi M, Ichikawa D, Kikuchi S, Okamoto K, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Otsuji E. The IL-6 and COX-2 expression related to sensitivity of chemoradiotherapy and prognosis in esophageal carcinoma. Gan To Kagaku. 2009;36:1979-1981.
64. Kim AH, Lebman DA, Dietz CM, Snyder SR, Eley KW, Chung TD. Transforming growth factor-β is an endogenous radioresistance factor in the esophageal adenocar-cinoma cell line OE-33. Int J Oncol. 2003;23:1593-1599.
65. Sun SP, Jin YN, Yang HP, Wei Y, Dong Z. Serum transforming growth factor-β1 level refects disease status in patients with esophageal carcinoma after radiotherapy. World J Gastroenterol. 2007;13:5267-5272.
66. Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)-induced genetic and epi-genetic alterations in human carcinogenesis. Mutat Res. 2011;711:167-173.
67. Farhadi A, Fields J, Banan A, Keshavarzian A. Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol. 2002;97:22-26.
68. Zhou X, Li D, Resnick MB, Behar J, Wands J, Cao W. Signaling in H2O2-induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. J Pharmacol Exp Ther. 2011;339:218-227.
69. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's meta-plasia-dysplasia-adenocarcinoma sequence. Am J Gas-troenterol. 2001;96:990-996.
70. Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol. 2004;2:880-887.
71. van Rooij E. The art of microRNA research. Circ Res. 2011;108:219-234.
72. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011;676:3-22.
73. Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology 2009;127:291-298.
74. Löffer D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330-1333.
75. Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Ogawa R, Katada T, Harata K, Tanaka T, Shiozaki M, Fujii Y. MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Report. 2009;2:235-9.